During the writing of this manuscript, exploratory analyses from two prospective studies performed in patients with advanced HCC have been published: Personeni et al. analysed the prognostic value of NLR in patients treated in the ARQ 197–215 study, a randomised placebo-controlled study testing the MET inhibitor tivantinib in the second line setting for patients with advanced HCC [30]. Here, MET is linked to hepatocellular carcinoma.